[1]陈赛,刘海艇,李铁,等.新型冠状病毒肺炎患者肝功能异常的相关临床分析[J].现代检验医学杂志,2020,35(05):103-105,117.[doi:10.3969/j.issn.1671-7414.2020.05.026]
　CHEN Sai,LIU Hai-ting,LI Tie,et al.Clinical Analysis of Abnormal Liver Function in Patients with New Coronavirus Pneumonia[J].Journal of Modern Laboratory Medicine,2020,35(05):103-105,117.[doi:10.3969/j.issn.1671-7414.2020.05.026]
点击复制

新型冠状病毒肺炎患者肝功能异常的相关临床分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年05期
页码:
103-105,117
栏目:
新型冠状病毒肺炎检验专题
出版日期:
2020-11-01

文章信息/Info

Title:
Clinical Analysis of Abnormal Liver Function in Patients with New Coronavirus Pneumonia
文章编号:
1671-7414（2020）05-103-04
作者:
陈赛1; 刘海艇1; 李铁2; 桂嵘1; 张军华1
1. 中南大学湘雅三医院输血科，长沙410013；2. 岳阳市第一人民医院检验科，湖南岳阳 414000
Author(s):
CHEN Sai1;  LIU Hai-ting1;  LI Tie2;  GUI Rong1;  ZHANG Jun-hua1
1.Department of Blood Transfusion,the Third Xiangya Hospital of Central South University, Changsha 410013,China; 2.Department of Clinical Laboratory, the First People’s Hospital of Yueyang, Hunan Yueyang 414000, China
关键词:
新型冠状病毒; 新型冠状病毒肺炎; 肝损伤
分类号:
R373.19；R446.12
DOI:
10.3969/j.issn.1671-7414.2020.05.026
文献标志码:
A
摘要:
目的　探讨新型冠状病毒肺炎（COVID-19）患者肝功能异常的相关性因素。方法　回顾性分析湖南省岳阳市 第一人民医院2020 年1~3 月收治的新型冠状病毒（SARS-CoV-2）感染患者80 例，根据肝功能情况分为肝功能异常 组45 例，对照组35 例，对其进行病例对照研究，选择与肝损伤有关指标进行单因素及多因素分析，探讨COVID-19 患者肝功能异常的发生机制。结果　研究显示肺炎严重程度是COVID-19 患者发生肝损伤的主要危险因素（P=0.009， OR=3.826，95%CI 1.388~10.544），而基础疾病、炎症因子水平与COVID-19 患者出现肝损伤无统计学相关性（P>0.05）。 结论　COVID-19 患者发生肝功能损害与病情进展密切相关，临床医生诊治患者时，应当遵从早发现、早治疗的原则， 避免造成肝脏进一步损伤，改善患者预后。
Abstract:
Objective　To explore the related factors of abnormal liver function in patients with COVID-19. Methods　A retrospective analysis of 80 patients with SARS-CoV-2 infetion admitted to the First People’s Hospital of Yueyang from January 1 to March 30, 2020, was carried out. According to the liver function, 45 cases entered abnormal liver function group and 35 cases entered control group. A case control study was conducted to explore factors related to abnormal liver function in patients with new pneumonia. Results　This study showed that the severity of pneumonia was a risk factor for liver injury in patients with COVID-19(P=0.009, OR=3.826, 95%CI 1.388 ~ 10.544), while the basic diseases and inflammatory factors level had nostatistical correlation withpatients with theliver injury of the patients with COVID-19 (P>0.05). Conclusion　The liver injury in patients with COVID-19 was closely related to the progression of the pneumonia. When treating patients, clinicians should follow the principles of early detection and early treatment to avoid further damage to the liver and to improve patients’ prognosis.

参考文献/References:

[1] WAN Yushun,SHANG Jian,GRAHAM R,et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus[J]. Journal of virology,2020, 94(7):e00127-20.
[2] TORTORICI M A,VEESLER D. Structural insights into coronavirus entry[J]. Advances in Virus Rsearch,2019,105:93-106.
[3] CHEN Nanshan, ZHOU Min, DONG Xuan, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet, 2020, 395(1223): 507-513.
[4] YANG Xiaobo, YU Yuan, XU Jiqian, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study[J]. The Lancet Respiratory Medicine, 2020, 8(5): 475-481.
[5] TANG Ning, LI Dengju, WANG Xiong, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. Journal of Thrombosis and Haemostasis, 2020, 18(4): 844-847.
[6] WANG Yixuan, WANG Yuyi, CHEN Yan, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures[J]. Journal of Medical Virology, 2020, 92(6): 568-576.
[7] CHAI Xiaoqiang, HU Longfei, ZHANG Yan, et al. Specific ACE2 expression in cholangiocytes May cause liver damage after 2019-nCoV infection[J].BioRxiv, 2020. DOI：10.1101/2020.02.03.931766
[8] 孙超，范建高. 加强新型冠状病毒肺炎患者肝损伤的 临床研究[J]. 实用肝脏病杂志, 2020, 23（2）:153-155. SUN Chao, FAN Jiangao. Strengthen clinical research on liver injury in patients with novel corona virus pneumonia[J]. Journal of Practical Hepatology ,2020,23(2):153-155.
[9] 汪姝惠，田德安，晏维. 新型冠状病毒肺炎患者肝 功能损伤的发生机制[J]. 胃肠病学和肝病学杂志， 2020, 29（3）: 262-264． WANG Shuhui, TIAN De’an, YAN Wei. Mechanism of liver function injury in patients with corona virus disease 2019[J]. Chinese Journal of Gastroenterology and Hepatology,2020,29(3):262-264.
[10] 中华人民共和国国家卫生健康委员会（国卫办医函 〔2020〕184 号）: 关于印发新型冠状病毒感染的肺 炎诊疗方案（试行第七版）的通知 [EB/OL].(2020- 03-04). http://www.nhc.gov.cn/xcs/zhengcwj/202003/4 6c9294a7dfe4cef80dc7f5912eb1989.shtml. National Health Commission of the People’s Republic of China (Medical Letter of the State Health Office
[2020] No. 184): Notification on the issuance of COVID-19 medical program (trial seventh edition) [EB/ OL].(2020-03-04). http://www.nhc.gov.cn/xcs/zhengcw j/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[11] HUANG Chaolin, WANG Yeming, LI Xingwang, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. The Lancet, 2020, 395(10223): 497-506.
[12] PAN Xiaoqi, ZHOU Jie, CHEN Yan,et al. Classification, hepatotoxic mechanisms, and targets of the risk ingredients in traditional Chinese medicine-induced liver injury[J]. Toxicology Letters,2020,323: 48-56.
[13] LU Hongzhou. Drug treatment options for the 2019- new coronavirus (2019-nCoV).[J]. Bioscience Trends,2020,14(1): 69-71.
[14] YE Qing, WANG Bili, MAO Jianhua. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19[J]. Journal of Infection, 2020, 80(6): 607-613.
[15] RIZZO P, VIECELI DALLA S F, FORTINI F, et al. COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm [J]. Basic research in cardiology,2020,115(3): 31.
[16] CHOUSTERMAN B G, SWIRSKI F K, WEBER G F. Cytokine storm and sepsis disease pathogenesis[J]. Seminars in Immunopathology, 2017, 39(5): 517-528.
[17] BOECKMANS J ,RODRIGUES R M, DEMUYSER T, et al. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point [J]. Archives of Toxicology,2020,94(4): 1367-1369.
[18] 王全华, 付辛芳, 虢艳宁, 等. 药物性肝损伤患者用 药情况及临床特征分析[J]. 检验医学与临床，2019, 16（24）: 3623-3626． WANG Quanhua, FU Xinfang, GUO Yanning, et al. Medication situation and characteristics of patients with drug-induced liver injury [J]. Laboratory Medicine and Clinic,2019,16(24):3623-3626.
[19] 母义明，纪立农，宁光，等．二甲双胍临床应用专 家共识(2018 年版)[J]. 中国糖尿病杂志, 2019, 27 （3）: 161-173． MU Yiming, JI Linong, NING Guang, et al. Chinese experts consensus statement on Metformin in the clinical practice:2018 updated[J]. Chinese Journal of Diabetes,2019,27(3):161-173.
[20] 张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因 子风暴及其药物治疗[J/OL]. 中国药学杂志, 2020,
[2020-02-25]. http://kns.cnki.net/kcms/detail/11.2162. R.20200225.1052.002.html. ZHANG Jingwen, HU Xin, JIN Pengfei. Cytokine storm induced by SARS-CoV-2 and the drug therapy[J]. Chinese Pharmaceutical Journal, 2020,
[2020-02-25]. http://kns.cnki.net/kcms/detail/11.2162. R.20200225.1052.002.html.
[21] 胡利琳, 王玮珺, 朱清静, 等. 新型冠状病毒肺炎相 关肝损伤：病因分析及治疗策略[J]. 中华肝脏病杂 志,2020,28(2):97-99. HU Lilin, WANG Weijun, ZHU Qingjing, et al. Novel coronavirus pneumonia-related liver injury: Etiologicalanalysis and treatment strategy[J]. Chin J Heaptol, 2020, 28(2): 97-99.
[22] WANG Dawei, HU Bo, HU Chang, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11):1061-1069.
[23] 徐祖龙，董苏荣，张亚明．WBC,CRP 和ESR 联合 检测在肺炎支原体肺炎中的意义[J]. 现代检验医学 杂志, 2015, 30（1）: 153-155, 158． XU Zulong, DONG Surong, ZHANG Yaming. Significance of combining with WBC,CRP and ESR detection in patients with Mycoplasma Pneumoniae pneumonia[J].Journal of Modern Laboratory Medicine,2015,30(01):153-155, 158.
[24] 黄允, 李艳, 彭锐, 等．HBV 感染致肝损伤患者 CRP, hsCRP 和SAA 临床价值的探讨[J]．现代检验 医学杂志, 2017, 32（2）: 49-52． HUANG Yun, LI Yan, PENG Rui, et al. Clinical Significance of SAA,CRP and hsCRP in HBV hepatopathy patients[J].Journal of Modern Laboratory Medicine, 2017,32(2):49-52.

相似文献/References:

[1]童　伟,陈登奕,陈俊文,等.2019-nCoV 总抗体两种免疫学检测方法的应用评价[J].现代检验医学杂志,2020,35(02):80.[doi:10.3969/j.issn.1671-7414.2020.02.023]
　TONG Wei,CHEN Deng-yi,CHEN Jun-wen,et al.Application Evaluation of Two Immunological Detection Methodsof 2019-nCoV Specific Antibodies[J].Journal of Modern Laboratory Medicine,2020,35(05):80.[doi:10.3969/j.issn.1671-7414.2020.02.023]
[2]谢　辉,刘玮玮b,郭　娟a,等.新型冠状病毒肺炎疫情下检验医学临床服务管理的探索[J].现代检验医学杂志,2020,35(03):81.[doi:10.3969/j.issn.1671-7414.2020.03.020]
　XIE Huia,LIU Wei-weib,GUO Juana,et al.Exploration on Clinical Service Management of Laboratory Medicine during COVID-19 Epidemic Period[J].Journal of Modern Laboratory Medicine,2020,35(05):81.[doi:10.3969/j.issn.1671-7414.2020.03.020]
[3]陈泽衍,马　雯,张立俊,等.荧光免疫层析法检测全血2019-nCoV IgM 和IgG 抗体在新型冠状病毒肺炎诊断中的应用[J].现代检验医学杂志,2020,35(03):84.[doi:10.3969/j.issn.1671-7414.2020.03.021]
　CHEN Ze-yan,MA Wen,ZHANG Li-jun,et al.Application of 2019-nCoV IgM and IgG Tests by Fluorescence Immunochromatography in the Diagnosis of 2019-nCoV Infections[J].Journal of Modern Laboratory Medicine,2020,35(05):84.[doi:10.3969/j.issn.1671-7414.2020.03.021]
[4]朱传新,周玉平,何　艳,等.92 例新冠肺炎病毒感染患者早期外周血白细胞形态分析[J].现代检验医学杂志,2020,35(03):94.[doi:10.3969/j.issn.1671-7414.2020.03.024]
　ZHU Chuan-xin,ZHOU Yu-ping,HE Yan,et al.Morphological Analysis of Early Peripheral Blood Leukocytes in 92 Patients with New Coronary Pneumonia[J].Journal of Modern Laboratory Medicine,2020,35(05):94.[doi:10.3969/j.issn.1671-7414.2020.03.024]
[5]刘艳霞,区静怡,黄 颖,等.新型冠状病毒肺炎患者外周血淋巴细胞及其亚群检测的临床意义[J].现代检验医学杂志,2020,35(04):94.[doi:10.3969/j.issn.1671-7414.2020.04.023]
　LIU Yan-xia,OU Jing-yi,HUANG Ying,et al.Clinical Significance of Detection of Peripheral Blood Lymphocyte and Its Subgroups in Patients with Coronavirus Disease 2019[J].Journal of Modern Laboratory Medicine,2020,35(05):94.[doi:10.3969/j.issn.1671-7414.2020.04.023]
[6]佟 丽,黄丽萍,石晓霞,等.血栓弹力图检测新型冠状病毒肺炎患者凝血功能的探讨分析[J].现代检验医学杂志,2020,35(04):97.[doi:10.3969/j.issn.1671-7414.2020.04.024]
　TONG Li,HUANG Li-ping,SHI Xiao-xia,et al.Investigation and Analysis of Thromboelastography in the Detection of COVID-19 Patients[J].Journal of Modern Laboratory Medicine,2020,35(05):97.[doi:10.3969/j.issn.1671-7414.2020.04.024]
[7]胡纪文,王恩运,阚丽娟,等.三种化学发光法检测新型冠状病毒（SARS-CoV-2）抗体试剂盒的临床应用评价[J].现代检验医学杂志,2020,35(04):100.[doi:10.3969/j.issn.1671-7414.2020.04.025]
　HU Ji-wen,WANG En-yun,KAN Li-juan,et al.Evaluation of Clinical Application of Three Chemiluminescence Detection Kits for Detection of Novel Coronavirus (SARS-CoV-2) Antibody[J].Journal of Modern Laboratory Medicine,2020,35(05):100.[doi:10.3969/j.issn.1671-7414.2020.04.025]
[8]白欢,沈玲,袁旭,等.新型冠状病毒肺炎患者早期外周血实验室检查结果分析[J].现代检验医学杂志,2020,35(05):93.[doi:10.3969/j.issn.1671-7414.2020.05.024]
　BAI Huan,SHEN Ling,YUAN Xu,et al.Analysis of the Characteristics of Hematological Parameters in the Early Stages of COVID-19[J].Journal of Modern Laboratory Medicine,2020,35(05):93.[doi:10.3969/j.issn.1671-7414.2020.05.024]
[9]闫美田,郑雨桐,孙艳美,等.新型冠状病毒肺炎患者血液CRP, CREA, ALB, IL-6 水平检测对疾病预后的应用价值分析[J].现代检验医学杂志,2020,35(05):106.[doi:10.3969/j.issn.1671-7414.2020.05.027]
　YAN Mei-tian,ZHENG Yu-tong,SUN Yan-mei,et al.Analysis of the Value of Detection of Blood CRP,CREA,ALB and IL-6 Level in Patients with New Coronavirus Pneumonia to the Prognosis of the Disease[J].Journal of Modern Laboratory Medicine,2020,35(05):106.[doi:10.3969/j.issn.1671-7414.2020.05.027]
[10]王琳琳a,张晓凝,王刚b,等.外周血白细胞参数对于新型冠状病毒肺炎诊断的临床意义[J].现代检验医学杂志,2020,35(05):110.[doi:10.3969/j.issn.1671-7414.2020.05.028]
　WANG Lin-lina,ZHANG Xiao-ning,WANG Gangb,et al.Clinical Significance of Peripheral Blood Leukocyte Parameters in the Diagnosis of COVID-19[J].Journal of Modern Laboratory Medicine,2020,35(05):110.[doi:10.3969/j.issn.1671-7414.2020.05.028]
[11]朱旭阳,叶寒青,陈文亥,等.新型冠状病毒肺炎患者血清SARS-CoV-2 抗体的检测分析[J].现代检验医学杂志,2020,35(04):106.[doi:10.3969/j.issn.1671-7414.2020.04.026]
　ZHU Xu-yang,YE Han-qing,CHEN Wen-hai,et al.Preliminary Analysis of Serum Antibodies Against SARS-CoV-2 in Patient with Coronavirus Disease 2019[J].Journal of Modern Laboratory Medicine,2020,35(05):106.[doi:10.3969/j.issn.1671-7414.2020.04.026]
[12]张园,周泽奇,王志贤,等.新型冠状病毒核酸、抗原和抗体联合检测的临床价值讨论[J].现代检验医学杂志,2020,35(05):99.[doi:10.3969/j.issn.1671-7414.2020.05.025]
　ZHANG Yuan,ZHOU Ze-qi,WANG Zhi-xian,et al.Discussion on the Clinical Value of Combined Detection of SARS-CoV-2 Nucleic Acid，Antigen and Antibody[J].Journal of Modern Laboratory Medicine,2020,35(05):99.[doi:10.3969/j.issn.1671-7414.2020.05.025]
[13]宁明哲,陶　月,陈雨欣,等.新型冠状病毒血清特异性抗体检测的假性问题分析和对策探讨[J].现代检验医学杂志,2020,35(06):129.[doi:doi:10.3969/j.issn.1671-7414.2020.06.031]
　NING Ming-zhe,TAO Yue,CHEN Yu-xin,et al.SARS-CoV-2 Serological Antibody Testing: Problems of FalseDetections and the Solutions[J].Journal of Modern Laboratory Medicine,2020,35(05):129.[doi:doi:10.3969/j.issn.1671-7414.2020.06.031]
[14]孟凡萍,郝　坡.新型冠状病毒肺炎患者外周血淋巴细胞亚群的分析研究[J].现代检验医学杂志,2021,36(02):114.[doi:doi:10.3969/j.issn.1671-7414.2021.02.027]
　MENG Fan-ping,HAO Po.Analysis of Peripheral Blood Lymphocyte Subsets in Patients with Novel Coronavirus Pneumonia[J].Journal of Modern Laboratory Medicine,2021,36(05):114.[doi:doi:10.3969/j.issn.1671-7414.2021.02.027]
[15]吴永彬,李　凌.CRISPR/Cas系统在新型冠状病毒肺炎快速诊断中的应用[J].现代检验医学杂志,2022,37(03):1.[doi:10.3969/j.issn.1671-7414.2022.03.001]
　WU Yong-bin,LI Ling.Application of CRISPR/Cas Systems in the Rapid Diagnosis of Coronavirus Disease 2019[J].Journal of Modern Laboratory Medicine,2022,37(05):1.[doi:10.3969/j.issn.1671-7414.2022.03.001]

备注/Memo

备注/Memo:
基金项目：湖南省自然科学基金- 青年基金项目（2019JJ50909）。
作者简介：陈赛（1997-），女，硕士研究生，研究方向：临床检验诊断学，E-mail：chensai@csu.edu.cn。
通讯作者：桂嵘，副教授，主任技师，博士生导师，E-mail: aguirong@163.com。 张军华, 博士，主管技师，E-mail: 1754142340@qq.com。
更新日期/Last Update: 2020-10-30